

Product Datasheet

LOXO-195

Catalog No. **BP-02341** · CAS **2097002-61-2** · Form **free base** · Physical state **solid** · Color **White to yellow** · Version **1.0** · Revision **2026-09-10**


FOR RESEARCH USE ONLY. NOT FOR HUMAN OR VETERINARY USE.

Target Trk Receptor	Research area Cancer
-------------------------------	--------------------------------

Molecular formula **C₂₀H₂₁FN₆O**

Molecular weight **380.4187**

STRUCTURE



DESCRIPTION

Selitrectinib (LOXO-195, BAY 2731954) is an orally available, highly potent, and selective TRK kinase inhibitor with low nanomolar inhibitory activity against TRKA G595R, TRKC G623R, and TRKA G667C.

BIOLOGICAL ACTIVITY

Selitrectinib (LOXO-195) is a potent and selective, next-generation TRK inhibitor, with IC₅₀ values of 0.6±0.1 nM, <2.5 nM for TRKA and TRKC, respectively. Selitrectinib (LOXO-195) achieves low nanomolar inhibitory activity against TRKA G595R, TRKC G623R, and TRKA G667C, with IC₅₀s ranging from 2.0-9.8 nM. LOXO-195 demonstrates potent inhibition of cell proliferation in TRK fusion-containing KM12, CUTO-3, and MO-91 cell lines (IC₅₀≤5 nM).

In diverse TRK fusion mouse models, Selitrectinib (LOXO-195) also causes inhibition of tumor growth relative to vehicle at all doses in four TRKA-dependent tumor models, superior to first generation TRK inhibitors, without significant toxicity.

SOLUBILITY

Soluble in DMSO

REFERENCES

[1]. Drilon A, et al. A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors. Cancer Discov. 2017, 7(9):963-972.

Tel: +86 20 31130026 · Fax: +86 20 36822386 · tech@biochemprobe.com · www.biochemprobe.com

BiochemProbe is the catalog brand of Guangzhou Yuyuan Biotech Co., Ltd. · For research use only.

Lot CoA and SDS are separate documents.